These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35159005)

  • 21. Combinatorial Effect of PLK1 Inhibition with Temozolomide and Radiation in Glioblastoma.
    Pandey A; Tripathi SC; Mai J; Hanash SM; Shen H; Mitra S; Rostomily RC
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib.
    Hong M; Ren M; Silva J; Kennedy T; Choi J; Cowell JK; Hao Z
    Am J Cancer Res; 2014; 4(2):135-47. PubMed ID: 24660103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Midostaurin: a magic bullet that blocks mast cell expansion and activation.
    Valent P; Akin C; Hartmann K; George TI; Sotlar K; Peter B; Gleixner KV; Blatt K; Sperr WR; Manley PW; Hermine O; Kluin-Nelemans HC; Arock M; Horny HP; Reiter A; Gotlib J
    Ann Oncol; 2017 Oct; 28(10):2367-2376. PubMed ID: 28945834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
    Nguyen T; Parker R; Hawkins E; Holkova B; Yazbeck V; Kolluri A; Kmieciak M; Rahmani M; Grant S
    Oncotarget; 2017 May; 8(19):31478-31493. PubMed ID: 28416758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.
    Alimova I; Pierce AM; Harris P; Donson A; Birks DK; Prince E; Balakrishnan I; Foreman NK; Kool M; Hoffman L; Venkataraman S; Vibhakar R
    Oncotarget; 2017 Nov; 8(57):97290-97303. PubMed ID: 29228610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
    Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
    Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.
    Kreahling JM; Gemmer JY; Reed D; Letson D; Bui M; Altiok S
    Mol Cancer Ther; 2012 Jan; 11(1):174-82. PubMed ID: 22084170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
    Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
    Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p21 limits S phase DNA damage caused by the Wee1 inhibitor MK1775.
    Hauge S; Macurek L; Syljuåsen RG
    Cell Cycle; 2019 Apr; 18(8):834-847. PubMed ID: 30943845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GSK3 inhibitors stabilize Wee1 and reduce cerebellar granule cell progenitor proliferation.
    Penas C; Mishra JK; Wood SD; Schürer SC; Roush WR; Ayad NG
    Cell Cycle; 2015; 14(3):417-24. PubMed ID: 25616418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
    Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
    Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
    Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
    Aichberger KJ; Mayerhofer M; Gleixner KV; Krauth MT; Gruze A; Pickl WF; Wacheck V; Selzer E; Müllauer L; Agis H; Sillaber C; Valent P
    Blood; 2007 Apr; 109(7):3031-41. PubMed ID: 17110460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate.
    Abdelfatah S; Berg A; Huang Q; Yang LJ; Hamdoun S; Klinger A; Greten HJ; Fleischer E; Berg T; Wong VKW; Efferth T
    Acta Pharm Sin B; 2019 Sep; 9(5):1021-1034. PubMed ID: 31649851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
    Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
    Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Polo-like kinase 1 during the DNA damage response is mediated through loss of Aurora A recruitment by Bora.
    Bruinsma W; Aprelia M; García-Santisteban I; Kool J; Xu YJ; Medema RH
    Oncogene; 2017 Mar; 36(13):1840-1848. PubMed ID: 27721411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Insights into the Pathogenesis of Systemic Mastocytosis.
    Li Z
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34063170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.